AMAM:NYE-Ambrx Biopharma Inc ADR (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 1.06

Change

-0.01 (-0.93)%

Market Cap

USD 0.04B

Volume

5.52K

Avg Analyst Target

USD 6.00 (+466.04%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AMAM Stock Forecast & Price:
Based on the Ambrx Biopharma Inc ADR stock forecasts from 2 analysts, the average analyst target price for Ambrx Biopharma Inc ADR is USD 6.00 over the next 12 months. Ambrx Biopharma Inc ADR’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Ambrx Biopharma Inc ADR is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Ambrx Biopharma Inc ADR’s stock price was USD 1.06. Ambrx Biopharma Inc ADR’s stock price has changed by -7.02% over the past week, -43.92% over the past month and -92.04% over the last year.

About Ambrx Biopharma Inc ADR (AMAM:NYE)

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.62 (+0.65%)

USD215.92B 32.65 3.02
BHVN Biohaven Pharmaceutical Holdin..

+0.23 (+0.15%)

USD10.90B N/A -15.30
DNA Ginkgo Bioworks Holdings

+0.09 (+3.21%)

USD5.25B N/A -1.31
RCUS Arcus Biosciences Inc

+1.37 (+5.59%)

USD1.82B 25.21 10.11
MYOV Myovant Sciences Ltd

+0.73 (+4.42%)

USD1.61B N/A -11.99
NUVB Nuvation Bio Inc

+0.09 (+4.33%)

USD0.45B N/A 2.22
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
ADCT Adc Therapeutics SA

+0.16 (+3.43%)

USD0.36B -99,999.99 -0.65
ZYME Zymeworks Inc

+0.24 (+4.55%)

USD0.32B 300.20 -0.50
LCTX Lineage Cell Therapeutics Inc

N/A

USD0.20B 3.63 -2.90

ETFs Containing AMAM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -88.26% 9% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.26% 9% F 1% F
Trailing 12 Months  
Capital Gain -92.30% 6% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.30% 6% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -18.72% 21% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.72% 21% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 35.92% 59% F 29% F
Risk Adjusted Return -52.11% 21% F 7% F
Market Capitalization 0.04B 42% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.16 77% C+ 99% A+
Price/Book Ratio 0.29 97% A+ 98% A+
Price / Cash Flow Ratio -0.92 19% F 76% C
EV/EBITDA 0.70 19% F 73% C
Management Effectiveness  
Return on Equity -54.12% 59% F 7% F
Return on Invested Capital -254.98% 8% F 2% F
Return on Assets -24.66% 63% D 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.77 89% B+ 74% C
Short Percent 139.23% 3% F 11% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector